

**TAB 101**

Roxane Laboratories, Inc (James F. McIntyre)  
Chicago, IL

February 26, 2009

1

UNITED STATES DISTRICT COURT

DISTRICT OF MASSACHUSETTS

-----X  
In Re: PHARMACEUTICAL )  
INDUSTRY AVERAGE WHOLESALE ) MDL No. 1456  
PRICE LITIGATION ) Civil Action No.  
-----X 01-12257-PBS

THIS DOCUMENT RELATES TO: )  
United States of America ex )  
rel. Ven-a-Care of the )  
Florida Keys, Inc., et al. )  
v. Boehringer Ingelheim )  
Corp., et al., Civil Action )  
No. 07-10248-PBS )

-----X

The videotaped 30(b)(6) deposition of  
Roxane Laboratories, Inc., Roxane Laboratories, Inc.  
n/k/a Boehringer Ingelheim Roxane, Inc., Boehringer  
Ingelheim Pharmaceuticals, Inc., and Boehringer  
Ingelheim Corporation by JAMES F. MCINTYRE

Chicago, Illinois

Thursday, February 26, 2009

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)  
Chicago, IL

February 26, 2009

8 (Pages 26 to 29)

<p style="text-align: right;">26</p> <p>1 Q. Take a moment to review. You can let me 2 know when you're ready for a couple questions. 3 A. I'm ready. 4 Q. Have you seen this document before? 5 A. Yes. 6 Q. Who is Hermann Tetzner? 7 A. Hermann Tetzner at this time was the 8 chief financial officer of BIC. 9 Q. Do you know if he had responsibilities on 10 behalf of BIPI? 11 A. Well, he's chief financial officer for 12 BIC, so as a part of the corporate parent company, 13 yes. 14 Q. Would that have included Roxane, his 15 responsibilities? 16 MS. RIVERA: Object to form. 17 BY THE WITNESS: 18 A. No direct responsibilities for Roxane, 19 no. 20 BY MR. FAUCI: 21 Q. Do you see the first page, the second 22 slide down, under the heading, "Why Restructure?"</p>	<p style="text-align: right;">28</p> <p>1 Q. -- "Restructure?" 2 A. -- "Restructure?" Sorry. 3 MS. RIVERA: It's okay. 4 BY THE WITNESS: 5 A. "We currently operate" -- what -- I'm 6 sorry, which paragraph again? 7 BY MR. FAUCI: 8 Q. It's the paragraph beginning with, "We 9 currently operate." 10 A. "We currently operate in the U.S. with a 11 variety of legal entities that do not necessarily 12 reflect the nature of our business. This results 13 in two sets of reporting: One in terms of legal 14 entities and another in terms of business." 15 Q. How did the Boehringer Ingelheim 16 companies report, quote, "in terms of legal 17 entities," quote? 18 A. Could you clarify the question? I'm not 19 quite sure. 20 Q. I'm not quite sure what it means either. 21 I'm -- I'm reading the -- I'm sure what the 22 question means.</p>
<p style="text-align: right;">27</p> <p>1 A. Yes. 2 Q. Can you read that first paragraph. 3 A. "The current legal and operational 4 structure of the U.S. business has evolved over 5 time and served well for a long period" -- 6 MS. RIVERA: Hold on. Hold on. 7 BY MR. FAUCI: 8 Q. I'm sorry, we're on different pages of 9 the document. If you go to -- 10 MS. RIVERA: Did you mean the second 11 slide -- 12 MR. FAUCI: Yes, the very first -- 13 MS. RIVERA: -- on the first page? 14 BY THE WITNESS: 15 A. All right. 16 BY MR. FAUCI: 17 Q. The very first page -- 18 A. Sorry. 19 Q. -- the second slide -- 20 A. Sorry. 21 Q. -- under the heading, "Why" -- 22 A. "Why" --</p>	<p style="text-align: right;">29</p> <p>1 A. Well, all of our operating units are 2 separate legal entities, so each one reported 3 separately. 4 Q. I'm looking at this -- well, let's maybe 5 take a step back. When was the first time you saw 6 this document? 7 A. I don't recall whether I saw this back at 8 the time of the project or not, but certainly 9 during the course of preparing for this deposition 10 I've seen it. 11 Q. Does this appear to be a presentation 12 that Mr. Tetzner made? 13 A. That's what it appears to be, yes. 14 Q. And the language you just read, he says - 15 - or the slide says, "We currently operate in the 16 U.S. with a variety of legal entities that do not 17 necessarily reflect the nature of our businesses. 18 This results in two sets of reporting: One in terms 19 of legal entities and another in terms of 20 businesses." Do you see that? 21 A. Yes. 22 Q. I'm trying to understand what -- what's</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)  
Chicago, IL

February 26, 2009

9 (Pages 30 to 33)

<p style="text-align: right;">30</p> <p>1 the difference between a -- a reporting that is in</p> <p>2 terms of legal entities as opposed to reporting in</p> <p>3 terms of businesses?</p> <p>4 A. Well, Roxane Laboratories is a legal</p> <p>5 entity. But the sales is sales and marketing, and</p> <p>6 -- and the operations piece is a manufacturing. We</p> <p>7 report separately in terms of -- of the -- the</p> <p>8 performance results for those two segments of that</p> <p>9 particular company, so we really had two businesses</p> <p>10 within that one legal entity. And that's what the</p> <p>11 organization was trying to -- reorganization was</p> <p>12 trying to fix.</p> <p>13 Q. Why was this regarded as something that</p> <p>14 needed to be fixed?</p> <p>15 A. The -- the manufacturing business, who</p> <p>16 was -- the COO was Rob Fromuth, reported directly</p> <p>17 to the CEO of the U.S.</p> <p>18 Q. Mr. Fromuth was a Roxane employee?</p> <p>19 A. Yes.</p> <p>20 Q. And who did he report to?</p> <p>21 A. Marti Carroll, CEO of the U.S. of BIC.</p> <p>22 Q. CEO -- CEO of BIC?</p>	<p style="text-align: right;">32</p> <p>1 Q. When did Marti Carroll become the CEO of</p> <p>2 BIC?</p> <p>3 A. End of 2002 or early 2003, I'm not sure.</p> <p>4 Q. Do you know who's -- who his predecessor</p> <p>5 was?</p> <p>6 A. Werner Gerstenberg.</p> <p>7 Q. And so prior to, when Mr. Gerstenberg was</p> <p>8 CEO of BIC, would Tom Russillo have reported to him</p> <p>9 then?</p> <p>10 A. Yes, I would suspect so.</p> <p>11 Q. The second paragraph reads, "This system</p> <p>12 often does not convey clearly the performance of</p> <p>13 our businesses and leads to complexity in</p> <p>14 interpreting how each business is faring. The</p> <p>15 accounting reconciliations between the legal</p> <p>16 entities and the businesses reduce but do not</p> <p>17 remove this complexity." Do you see that?</p> <p>18 A. Yes.</p> <p>19 Q. What is an accounting reconciliation?</p> <p>20 A. To identify -- basically identifying the</p> <p>21 costs that are related to the marketing side of the</p> <p>22 business versus the manufacturing side of the</p>
<p style="text-align: right;">31</p> <p>1 A. Yes. And he was responsible for</p> <p>2 operations, our manufacturing.</p> <p>3 Q. I believe the question I had asked</p> <p>4 earlier was: Why was this situation regarded as a</p> <p>5 problem that needed to be fixed?</p> <p>6 A. Well, the sales and marketing side of the</p> <p>7 business, who was the vice president or general</p> <p>8 manager of the -- the -- the multi-source or the</p> <p>9 generic business for Roxane Laboratories, reported</p> <p>10 to someone different.</p> <p>11 Q. Who was that person? Who -- who was the</p> <p>12 person in charge of the marketing and sales of</p> <p>13 Roxane Laboratories?</p> <p>14 A. Paul Kersten.</p> <p>15 Q. When was Mr. Kersten in charge of that?</p> <p>16 A. Oh, at least since 2001. I don't know if</p> <p>17 it goes back any further than that.</p> <p>18 Q. And who did he report to?</p> <p>19 A. He reports to -- at that time, 2001, Tom</p> <p>20 Russillo.</p> <p>21 Q. Do you know who Mr. Russillo reported to?</p> <p>22 A. Marti Carroll.</p>	<p style="text-align: right;">33</p> <p>1 business.</p> <p>2 Q. What do you mean, "identifying"?</p> <p>3 A. I'm sorry?</p> <p>4 Q. Can you clarify what you mean by</p> <p>5 "identifying the" --</p> <p>6 A. If we --</p> <p>7 Q. -- "costs"?</p> <p>8 A. -- want to separate, we can identify</p> <p>9 which costs go with the sales -- sales side of the</p> <p>10 business versus which costs go with the</p> <p>11 manufacturing side of the business. By having</p> <p>12 those two legal entities together, that was a diff</p> <p>13 -- that was a challenge.</p> <p>14 Q. When would an accounting reconciliation</p> <p>15 have been performed?</p> <p>16 A. Every month.</p> <p>17 Q. Do you know if Roxane and BIPI had their</p> <p>18 own internal accounting systems?</p> <p>19 A. Roxane and BIPI -- beginning --</p> <p>20 MS. RIVERA: Object to form. Sorry.</p> <p>21 MR. FAUCI: It's all right.</p> <p>22 BY THE WITNESS:</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)  
Chicago, IL

February 26, 2009

17 (Pages 62 to 65)

<p style="text-align: right;">62</p> <p>1 A. Apparently, it says so, yes.</p> <p>2 Q. Mr. Russillo testified that</p> <p>3 notwithstanding his responsibilities for Roxane, he</p> <p>4 was on the Ben Venue payroll, and he was not paid</p> <p>5 by Roxane. I'm on page 23 of his January 8, 2009,</p> <p>6 deposition. And I'll just read you what he said.</p> <p>7 "Answer: I told you earlier my paycheck</p> <p>8 came from Ben Venue.</p> <p>9 "Question: Your paycheck came from Ben</p> <p>10 Venue?</p> <p>11 "Answer: Yes.</p> <p>12 "Question: Did your paycheck ever come</p> <p>13 from any other Boehringer Ingelheim entities from</p> <p>14 the period of November 1997 until 2005?</p> <p>15 "Answer: I don't believe so."</p> <p>16 My question to you was: Was there any</p> <p>17 formal accounting mechanism within Boehringer</p> <p>18 Ingelheim for Roxane to reimburse Ben Venue for</p> <p>19 work Mr. Russillo did on Roxane's behalf?</p> <p>20 A. Not to my --</p> <p>21 MS. RIVERA: Object --</p> <p>22 BY THE WITNESS:</p>	<p style="text-align: right;">64</p> <p>1 A. 2005.</p> <p>2 Q. Do you know when they started going on</p> <p>3 Ben Venue's payroll?</p> <p>4 MS. RIVERA: Object to --</p> <p>5 BY THE WITNESS:</p> <p>6 A. Not --</p> <p>7 MS. RIVERA: -- form and foundation.</p> <p>8 BY THE WITNESS:</p> <p>9 A. Not exactly.</p> <p>10 BY MR. FAUCI:</p> <p>11 Q. What was the mechanism whereby Roxane</p> <p>12 paid for the services?</p> <p>13 A. There was accounting entries to charge</p> <p>14 back for Roxane legal entity.</p> <p>15 Q. Do you know how their salaries were</p> <p>16 allocated?</p> <p>17 A. They were completely allocated. All the</p> <p>18 Roxane Laboratories sales and marketing people were</p> <p>19 completely allocated to the Roxane legal entity.</p> <p>20 Q. So if a employee had responsibilities on</p> <p>21 behalf of both companies, would his salary be</p> <p>22 allocated to both companies?</p>
<p style="text-align: right;">63</p> <p>1 A. -- knowledge.</p> <p>2 MS. RIVERA: -- to form and foundation.</p> <p>3 BY THE WITNESS:</p> <p>4 A. Not to my knowledge. It was for the</p> <p>5 other sales and marketing people though.</p> <p>6 BY MR. FAUCI:</p> <p>7 Q. What do -- say that again.</p> <p>8 A. There was reimbursement for the other</p> <p>9 sales and marketing people that were on Ben Venue</p> <p>10 payroll but worked for our -- for Roxane. Those</p> <p>11 costs were charged back to Roxane.</p> <p>12 Q. Which sales and marketing people do you</p> <p>13 have in mind?</p> <p>14 A. The Roxane Laboratories sales and</p> <p>15 marketing.</p> <p>16 Q. Can you give me some names?</p> <p>17 A. Paul Kersten, Judy Waterer, Leslie</p> <p>18 Paoletti.</p> <p>19 Q. So those people were on Ben Venue's</p> <p>20 payroll?</p> <p>21 A. At that time, yes.</p> <p>22 Q. Which -- at what time?</p>	<p style="text-align: right;">65</p> <p>1 A. I don't know that.</p> <p>2 Q. Would that be reflected in accounting</p> <p>3 records, the allocation?</p> <p>4 A. Yes.</p> <p>5 Q. Would it show up on a Roxane income</p> <p>6 statement?</p> <p>7 A. You'd have to drill down to the cost</p> <p>8 center level. We wouldn't see it specifically on</p> <p>9 the income statement.</p> <p>10 Q. And so you may have gathered I'm not the</p> <p>11 most sophisticated accounting person in the world.</p> <p>12 You say drill down to where?</p> <p>13 A. The cost center level.</p> <p>14 Q. What does that mean?</p> <p>15 A. It's a department.</p> <p>16 Q. And so if you drill down far enough</p> <p>17 somewhere, there would be a record that employee X</p> <p>18 was paid by Ben Venue but did work on behalf of</p> <p>19 Roxane, and then how would that be accounted for?</p> <p>20 A. It would be charged back to Roxane, and</p> <p>21 you'd see it in the sales and marketing department</p> <p>22 cost center.</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)  
Chicago, IL

February 26, 2009

18 (Pages 66 to 69)

<p style="text-align: right;">66</p> <p>1 Q. But you don't know if that happened for</p> <p>2 Mr. Russillo?</p> <p>3 A. I don't know.</p> <p>4 Q. I'm just -- why -- can you think of a</p> <p>5 reason why it would have happened for people like</p> <p>6 Judy Waterer and Leslie Paoletti but not for Mr.</p> <p>7 Russillo?</p> <p>8 MS. RIVERA: Object to form and</p> <p>9 foundation.</p> <p>10 BY THE WITNESS:</p> <p>11 A. They -- those folks were fully allocated</p> <p>12 to Roxanne. They didn't do any work for Ben Venue</p> <p>13 Laboratories.</p> <p>14 MR. FAUCI: I think it's time just to</p> <p>15 take a five-minute break.</p> <p>16 THE VIDEOGRAPHER: We are off the record</p> <p>17 at 10:03 a.m.</p> <p>18 (WHEREUPON, a recess was had.)</p> <p>19 THE VIDEOGRAPHER: We are back on the</p> <p>20 record at 10:18 a.m.</p> <p>21 (WHEREUPON, MS. DOLAN entered the</p> <p>22 deposition proceedings.)</p>	<p style="text-align: right;">68</p> <p>1 Mr. Sicora testified: "My paycheck said</p> <p>2 'Boehringer Ingelheim,' but all of the interactions</p> <p>3 were with Roxane."</p> <p>4 "Question: All right. Who did you</p> <p>5 believe was your employer?</p> <p>6 "Answer: Roxane."</p> <p>7 My question to you is: For employees</p> <p>8 such as Mr. Sicora, that said they were paid by</p> <p>9 Boehringer Ingelheim but had Roxane job</p> <p>10 responsibilities, would that have been allocated,</p> <p>11 as well?</p> <p>12 A. Yes.</p> <p>13 Q. Similar to the way that --</p> <p>14 A. Well --</p> <p>15 Q. Oh, go on.</p> <p>16 A. -- if I could clarify. I don't think it</p> <p>17 would be allocated. It'd be a direct charge as</p> <p>18 opposed to an allocation.</p> <p>19 Q. What is the difference?</p> <p>20 A. The difference is if he's a -- if he's a</p> <p>21 Roxane legal entity employee, it would be a direct</p> <p>22 charge as payroll -- when they cut the payroll</p>
<p style="text-align: right;">67</p> <p>1 BY MR. FAUCI:</p> <p>2 Q. Mr. McIntyre, a moment ago you testified</p> <p>3 that people in the Roxane sales and marketing</p> <p>4 department, such as Leslie Paoletti and Judy</p> <p>5 Waterer, though they were paid by Ben Venue, their</p> <p>6 salaries were allocated back to Roxane, do you</p> <p>7 recall that?</p> <p>8 A. Yes.</p> <p>9 Q. Do you know when that started?</p> <p>10 A. Not -- not for certain, no.</p> <p>11 Q. Do you know if it would've started before</p> <p>12 the 2005 reorg?</p> <p>13 A. Yes.</p> <p>14 Q. Do you know who Robert Sicora is?</p> <p>15 A. No.</p> <p>16 Q. I'll represent to you that he is or was</p> <p>17 the director of national accounts.</p> <p>18 A. For?</p> <p>19 Q. Well, we'll get -- we're going to get</p> <p>20 into that briefly.</p> <p>21 Mr. Sicora testified -- this is his</p> <p>22 December 4, 2008, deposition, at page 50.</p>	<p style="text-align: right;">69</p> <p>1 check, it would hit right into his particular cost</p> <p>2 center as opposed to an accounting entry that would</p> <p>3 be an allocation.</p> <p>4 Q. If he testified he was paid by BIPI,</p> <p>5 would your answer be the same?</p> <p>6 MS. RIVERA: Hold on. Object to form,</p> <p>7 misstates the testimony.</p> <p>8 BY THE WITNESS:</p> <p>9 A. I mean, you're -- it calls for</p> <p>10 speculation, I think. If he was paid by dippy --</p> <p>11 BIPI, no, then -- then it would have to be an</p> <p>12 allocation. But I don't know that he said he was</p> <p>13 paid by BIPI.</p> <p>14 BY MR. FAUCI:</p> <p>15 Q. No, it's -- I'm not sure he did either.</p> <p>16 He said he was paid by Boehringer Ingelheim.</p> <p>17 A. I think in those days, all our checks</p> <p>18 said, "Boehringer Ingelheim."</p> <p>19 Q. Someone in the Roxane contracts</p> <p>20 department -- well, strike that.</p> <p>21 MR. FAUCI: Let me introduce an exhibit.</p> <p>22 (WHEREUPON, there was some</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)

February 26, 2009

Chicago, IL

21 (Pages 78 to 81)

<p style="text-align: right;">78</p> <p>1 MS. RIVERA: Yeah, I was just several 2 pages in. 3 MR. FAUCI: I'm on the top paragraph. 4 MS. RIVERA: Okay. 5 MR. FAUCI: I'll read it again. 6 BY MR. FAUCI: 7 Q. Mr. Berkle says: "Again, in the context 8 that Roxane preemptively launched Ipratropium prior 9 to any other generic competitors had a cost from a 10 BIPI perspective. It allowed sales for the Roxane 11 product at a lesser price than the branded price at 12 a time when Atrovent still was patent protected." 13 My question to you is: Did Roxane pay 14 any money to BIPI for the right to market 15 Ipratropium Bromide at a time when BIPI still had a 16 patent protection for Atrovent? 17 A. They paid the 11 percent royalty. 18 Q. The same 11 percent royalty they paid 19 after Atrovent was no longer patent protected? 20 A. Yes. 21 MR. FAUCI: What are we on, Exhibit 7? 22 I'm going to introduce Exhibit 7.</p>	<p style="text-align: right;">80</p> <p>1 She was -- I don't know exact -- I don't recall her 2 exact position at this time. 3 Q. It's a e-mail. The subject of the e-mail 4 is: "Atrovent UDV," and then it says, "AM11," 5 slash, "US." Ms. Maloney writes, "BIPI is the 6 holder for the Atrovent NDA. Roxane distributes 7 the generic product Ipratropium Bromide legally out 8 of the NDA. Also, Novation distributes Ipratropium 9 Bromide out of the NDA. All three products are 10 manufactured by Roxane." Do you see that? 11 A. Yes. 12 Q. Does this refresh your recollection as to 13 whether at least by 1999 Roxane had filed an ANDA 14 for Ipratropium Bromide UDV? 15 A. It doesn't say that they filed an ANDA. 16 Q. And it actually says that Roxane 17 distributes the generic product out of the NDA, 18 which was held by BIPI; correct? 19 A. Correct. 20 Q. It also says that all three products are 21 manufactured by Roxane. Do you see that? 22 A. Yes.</p>
<p style="text-align: right;">79</p> <p>1 (WHEREUPON, a certain document was 2 marked Exhibit McIntyre 007, for identification.) 3 BY MR. FAUCI: 4 Q. This is a series of e-mails in the August 5 to October 1999 time frame. I'm going to direct 6 your attention to the third page of the document, 7 an e-mail -- feel free to read it all to get 8 familiarized at any time. I'm focusing on the 9 August 9, 1999, e-mail from Ann Maloney, sent at 10 1:18 p.m. Do you see that? 11 A. Yes. 12 MS. RIVERA: Yeah, Jim, you should make 13 sure you look at the whole document just to make 14 sure you're familiar with it. 15 Ready? 16 THE WITNESS: Yes. 17 BY MR. FAUCI: 18 Q. Ms. Maloney writes -- well, do you know 19 who Ms. Maloney is? 20 A. Yes. 21 Q. Who is she? 22 A. Well, she's no longer with the company.</p>	<p style="text-align: right;">81</p> <p>1 Q. Roxane manufactured Atrovent? 2 A. Yes. 3 Q. When did that start? Focusing on the 4 Atrovent UDV. 5 A. UDV, 1993, I believe. 6 Q. Did Roxane sell Atrovent to BIPI? 7 MS. RIVERA: Object to form. 8 BY THE WITNESS: 9 A. Yes, they would've sold the -- the 10 Atrovent UDV would've been sold to -- to -- to BIPI 11 by RLI. 12 BY MR. FAUCI: 13 Q. And then BIPI would turn around and 14 market and sell the products to customers under a 15 BIPI label? 16 A. That's correct. 17 Q. Were there written contracts evidencing 18 sales of Atrovent from Roxane to BIPI? 19 A. Yes, I believe there was a 1993 contract 20 manufacturing agreement. 21 Q. And that contract would have governed for 22 the life of Atrovent UDV?</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)  
Chicago, IL

February 26, 2009

22 (Pages 82 to 85)

<p style="text-align: right;">82</p> <p>1 A. My recollection is, it's a ten-year 2 contract, renewable. 3 Q. How was the price -- the sale price from 4 Roxane to BIPI determined? 5 A. Cost plus. 6 Q. What does that mean? 7 A. Manufacturing cost plus some -- some 8 markup. 9 Q. What does "manufacturing cost" mean? 10 A. Manufacturing cost is the cost of all the 11 ingredients plus labor and overhead. 12 Q. Where did Roxane get the ingredients? 13 A. The -- the active ingredient would have 14 come from BII. The Ipratropium Bromide is the 15 active ingredient. 16 Q. And they would have purchased that from 17 the German parent? 18 A. Yes. 19 Q. And they -- 20 A. Well, I can't be sure. It could've come 21 from BIPI, 'cause BIPI purchased Ipratropium from 22 other products, but -- but it's a BII product.</p>	<p style="text-align: right;">84</p> <p>1 THE VIDEOGRAPHER: We are back on the 2 record at 10:50 a.m. with the start of tape number 3 two. 4 BY MR. FAUCI: 5 Q. We were just talking about the process by 6 which Roxane sold Atrovent to BIPI. Do you 7 remember that? 8 A. Yes. 9 Q. And you said that it sold it at cost 10 plus, do you recall that? 11 A. Yes. 12 Q. And we were trying to educate me and the 13 jury on what cost plus meant. And you said that 14 cost includes the ingredient costs, the labor costs 15 and the overhead costs, do you recall that? 16 A. Yes. 17 Q. What's the plus? 18 A. The margin. 19 Q. Do you recall what the margin was? 20 A. No. In the 1993 contract, we were unable 21 to determine exactly what the margin would have 22 been and how that pricing was determined for that -</p>
<p style="text-align: right;">83</p> <p>1 Q. So they would buy the -- the active 2 ingredient -- Roxane would buy the active 3 ingredient from another Boehringer Ingelheim 4 entity? 5 A. Yes. 6 Q. And then Roxane would manufacture it? 7 A. Yes. 8 Q. And you said that the cost included what 9 else besides the ingredient costs? 10 A. Labor and overhead. 11 Q. What's included in overhead? 12 A. General plan overhead, depreciation of 13 the equipment, depreciation of building, travel 14 expenses. There's a whole list of items that are 15 part of overhead. 16 MR. FAUCI: I think we need to take a 17 break. 18 THE VIDEOGRAPHER: We are off the record 19 at 10:39 a.m. with the end of tape number one. 20 (WHEREUPON, a recess was had.) 21 (WHEREUPON, MS. DOLAN left the 22 deposition proceedings.)</p>	<p style="text-align: right;">85</p> <p>1 - and during that time frame. 2 Q. So what was the result? 3 A. I'm not sure I understand the question. 4 Q. Oh, when you say you were unable to 5 determine what the margin was, what do you mean? 6 In preparation for today? 7 A. Yes. 8 Q. But there was a margin in the 1993 9 contract that -- 10 A. I'd have to -- 11 Q. -- presumably? 12 A. -- believe that there was, yes. 13 Q. Do you know what the margin was at any 14 point in time from 1996 to the present? 15 A. Yes. 16 Q. What was it, and when did it become that? 17 A. We're talking specifically about 18 Ipratropium Bromide UDVs? 19 Q. Atrovent UDV. 20 A. Atrovent -- Atrovent UDVs. Well, 21 Atrovent UDVs were discontinued in 2003, so -- 22 Q. Okay.</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com



Roxane Laboratories, Inc (James F. McIntyre)  
Chicago, IL

February 26, 2009

23 (Pages 86 to 89)

<p style="text-align: right;">86</p> <p>1 A. -- but be -- up until 2003, the margin</p> <p>2 was based -- was 2.2 percent, based on full cost.</p> <p>3 Q. What does that mean, "based on full</p> <p>4 cost"?</p> <p>5 A. Well, it includes the cost of the active</p> <p>6 ingredient.</p> <p>7 Q. In addition to the labor and the</p> <p>8 overhead?</p> <p>9 A. Labor and the overhead, that's --</p> <p>10 Q. How was --</p> <p>11 A. -- correct.</p> <p>12 Q. -- the 2.2 percent figure arrived at?</p> <p>13 A. 2.2 percent on total cost is -- gives --</p> <p>14 gives the same absolute margin or absolute profit</p> <p>15 as ten percent on cost minus API.</p> <p>16 Q. What is "API"?</p> <p>17 A. Active pharmaceutical ingredient; that's</p> <p>18 the Ipratropium Bromide. The way we do things</p> <p>19 today is we charge ten percent on only third-party</p> <p>20 acquired materials.</p> <p>21 Q. Materials acquired from outside --</p> <p>22 A. Outside, nonaffiliate companies. If it</p>	<p style="text-align: right;">88</p> <p>1 Q. And I understand that the -- why the 2.2</p> <p>2 was used in place of the ten percent, but how was</p> <p>3 the 2.2 number arrived at?</p> <p>4 A. Because it gave the same -- as I</p> <p>5 mentioned, it gave the same level of profit as</p> <p>6 using ten percent on a cost excluded the API.</p> <p>7 Q. Was it negotiated?</p> <p>8 A. Yes, and later -- later validated by</p> <p>9 outside consultants.</p> <p>10 Q. And would this 2.2 percent or ten percent</p> <p>11 markup have been true on all the products that</p> <p>12 Roxane manufactured for Boehringer Ingelheim</p> <p>13 entities?</p> <p>14 A. Yes.</p> <p>15 Q. Let me show you a document marked Exhibit</p> <p>16 8.</p> <p>17 (WHEREUPON, a certain document was</p> <p>18 marked Exhibit McIntyre 008, for identification.)</p> <p>19 BY THE WITNESS:</p> <p>20 A. 1998 Expectation and Budget.</p> <p>21 BY MR. FAUCI:</p> <p>22 Q. It's a September 30, 1998, document, that</p>
<p style="text-align: right;">87</p> <p>1 has affiliate material in there, we subtract that</p> <p>2 from the total cost, because that affiliate</p> <p>3 material already has some markup, so we don't --</p> <p>4 it's not fair to mark it up twice.</p> <p>5 Q. Okay. So focusing on the Atrovent UDV,</p> <p>6 that there would be some markup applied to the</p> <p>7 ingredient that Roxane would have purchased from</p> <p>8 either BIPI or BII?</p> <p>9 A. Based -- yes, based on the way we do it</p> <p>10 now or did it in -- from -- up until 2003.</p> <p>11 Q. And so based on the way it was done up</p> <p>12 until 2003?</p> <p>13 A. Yes.</p> <p>14 Q. And because of that, the margin from</p> <p>15 Roxane to BIPI was only 2.2 percent, is that</p> <p>16 correct?</p> <p>17 A. At that time, yes. We don't know what it</p> <p>18 was back in '93.</p> <p>19 Q. When did it become 2.2 percent?</p> <p>20 A. About that time, 2001, 2002.</p> <p>21 Q. And it stayed that way until 2003?</p> <p>22 A. Yeah, we discontinued the product.</p>	<p style="text-align: right;">89</p> <p>1 says, "Commentary, 1998 Expectation, 1999 Budget,</p> <p>2 Roxane Laboratories, Incorporated." Take a moment</p> <p>3 to familiarize yourself with it, but I will be</p> <p>4 asking you questions about specific parts.</p> <p>5 A. Okay. Okay.</p> <p>6 Q. Are you familiar with this document?</p> <p>7 A. I've never seen this particular one, but</p> <p>8 I'm somewhat familiar with it, yes.</p> <p>9 Q. What is an expectation?</p> <p>10 A. Expectation is an update of the current</p> <p>11 year. So when you start out the year, you have</p> <p>12 your budget; later in the year, we do an update of</p> <p>13 what that budget is and what the expectation -- I</p> <p>14 mean, what we're gonna come in at at the end of --</p> <p>15 the end of the year. So it's our projection for</p> <p>16 what our actual costs or what our actual will be by</p> <p>17 December 31st.</p> <p>18 Q. So it's --</p> <p>19 A. So it has no actual numbers, per se, in</p> <p>20 there.</p> <p>21 Q. It's the revised budget based on the</p> <p>22 year-to-date?</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)

February 26, 2009

Chicago, IL

30 (Pages 114 to 117)

<p style="text-align: right;">114</p> <p>1 MS. RIVERA: -- my objection for the</p> <p>2 record that Roxane's agreements and -- with its</p> <p>3 customers and contracts with its customers falls</p> <p>4 into the subject matter of that --</p> <p>5 MR. FAUCI: That's --</p> <p>6 MS. RIVERA: -- of that topic and doesn't</p> <p>7 pertain to sales of those drugs between the</p> <p>8 companies.</p> <p>9 MR. FAUCI: I think how -- this is just</p> <p>10 for the record, but I -- it's my position that how</p> <p>11 rebates were booked for sales of Roxane's products,</p> <p>12 including rebates on BIPI's products, falls</p> <p>13 squarely within the topic that is about Defendants'</p> <p>14 practices, including accounting practices, with</p> <p>15 respect to sales of certain products. But your</p> <p>16 objection is on the record.</p> <p>17 BY MR. FAUCI:</p> <p>18 Q. So my question was: Do you know which</p> <p>19 company, Roxane or BIPI, paid this rebate?</p> <p>20 A. No, I do not.</p> <p>21 Q. Who would I talk to to find that out?</p> <p>22 A. I -- I don't know.</p>	<p style="text-align: right;">116</p> <p>1 "Which company pays the rebate; BIPI, RLI or both?</p> <p>2 This is still being decided upon. We'll have to</p> <p>3 make the decision based on what is most cost</p> <p>4 effective for the combined companies. We'll need</p> <p>5 to plan to do it either way until it's resolved.</p> <p>6 Hopefully, we'll have the final answer in a week or</p> <p>7 two." Do you see that?</p> <p>8 A. I see that.</p> <p>9 Q. What do you understand Ms. Waterer to</p> <p>10 mean when she writes "the combined companies"?</p> <p>11 MS. RIVERA: Object to form and</p> <p>12 foundation.</p> <p>13 BY THE WITNESS:</p> <p>14 A. I can't speak to what she meant.</p> <p>15 BY MR. FAUCI:</p> <p>16 Q. Can you think of a reason why BIPI would</p> <p>17 pay a rebate -- the rebate described in the Exhibit</p> <p>18 13?</p> <p>19 MS. RIVERA: Object to form and</p> <p>20 foundation.</p> <p>21 BY THE WITNESS:</p> <p>22 A. No, I don't know why.</p>
<p style="text-align: right;">115</p> <p>1 Q. I want to show you a document the court</p> <p>2 reporter's gonna mark as Exhibit 14.</p> <p>3 (WHEREUPON, a certain document was</p> <p>4 marked Exhibit McIntyre 014, for identification.)</p> <p>5 MR. FAUCI: Oops, I wrote on yours.</p> <p>6 MS. RIVERA: That's okay.</p> <p>7 MR. FAUCI: I think I have an extra, so.</p> <p>8 MS. RIVERA: What are we on, 13?</p> <p>9 MR. FAUCI: I think we're on 14.</p> <p>10 (WHEREUPON, MS. DENTON entered the</p> <p>11 deposition proceedings.)</p> <p>12 BY MR. FAUCI:</p> <p>13 Q. This is a November 20, 1997, e-mail from</p> <p>14 Judy Waterer to Dave Roberts, subject is:</p> <p>15 "Respiratory Bundle." Are you familiar with this</p> <p>16 document?</p> <p>17 A. No.</p> <p>18 Q. In bold, do you see where it says,</p> <p>19 "Discussion Questions Related to Proposed</p> <p>20 Respiratory Bundling Agreements"?</p> <p>21 A. I see that, yes.</p> <p>22 Q. And do you see the fourth bullet down,</p>	<p style="text-align: right;">117</p> <p>1 MR. FAUCI: I think we're at a natural</p> <p>2 breaking point.</p> <p>3 MS. RIVERA: Okay.</p> <p>4 MR. FAUCI: We're going to go in a</p> <p>5 different direction after this.</p> <p>6 MS. RIVERA: Okay.</p> <p>7 THE VIDEOGRAPHER: We are off the record</p> <p>8 at 11:31 a.m.</p> <p>9 (WHEREUPON, a recess was had.)</p> <p>10 THE VIDEOGRAPHER: We are back on the</p> <p>11 record at 11:50 a.m.</p> <p>12 BY MR. FAUCI:</p> <p>13 Q. I have a few more questions about the</p> <p>14 period of time in 1996 when Atrovent was</p> <p>15 substituted for generic Ipratropium Bromide.</p> <p>16 Roxane and BIPI are separate companies, correct?</p> <p>17 A. Correct.</p> <p>18 Q. And just to recapture this, when Roxane</p> <p>19 had a shortage of its generic Ipratropium Bromide</p> <p>20 product, BIPI allowed Roxane to substitute Atrovent</p> <p>21 in its place; is that correct?</p> <p>22 A. That's correct.</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)

February 26, 2009

Chicago, IL

31 (Pages 118 to 121)

<p style="text-align: right;">118</p> <p>1 Q. And, in fact, the -- the sales prices for</p> <p>2 generic Ipratropium were -- in effect, the sales</p> <p>3 were at Roxane's generic prices; is that right?</p> <p>4 A. To the customers, sales to the customers?</p> <p>5 Q. Yes.</p> <p>6 A. Yes, I believe that's the case.</p> <p>7 Q. And so the sales price that BIPI booked</p> <p>8 was -- was well within its average sales price for</p> <p>9 Atrovent, correct?</p> <p>10 A. That's correct.</p> <p>11 Q. Please explain to the jury why BIPI would</p> <p>12 allow Roxane to sell its Atrovent product at a</p> <p>13 reduced price.</p> <p>14 MS. RIVERA: Object to form.</p> <p>15 Go ahead.</p> <p>16 BY THE WITNESS:</p> <p>17 A. Well, in this particular case, it was</p> <p>18 because BIPI had distressed product. They had --</p> <p>19 they -- they had product that was gonna go short</p> <p>20 code and would've had been destroyed had it not had</p> <p>21 the opportunity to sell it through the Roxane</p> <p>22 customers. So it represented a win-win, that we</p>	<p style="text-align: right;">120</p> <p>1 A. Uh-huh.</p> <p>2 Q. She writes, "I plan to take the</p> <p>3 discounted product to select customers that will be</p> <p>4 the least likely to divert it." Do you see that?</p> <p>5 A. Yes.</p> <p>6 Q. "The customers that have been identified</p> <p>7 as likely targets for Atrovent substitution of</p> <p>8 generic IB-UDV are direct warehousing retail</p> <p>9 chains, Accurate, and RDI." Do you see that?</p> <p>10 A. Yes.</p> <p>11 Q. Please tell me your testimony as to why</p> <p>12 Roxane chose not to sell Atrovent at generic prices</p> <p>13 to wholesalers.</p> <p>14 A. My understanding from the wholesale --</p> <p>15 the way the business works with wholesalers is that</p> <p>16 it takes too long to get through their distribution</p> <p>17 channel, and that's -- and that's when this product</p> <p>18 might expire.</p> <p>19 Q. Ms. Waterer writes that she plans to take</p> <p>20 the disproduct -- discounted product to select</p> <p>21 customers that will be the least likely to divert</p> <p>22 it. What does that mean?</p>
<p style="text-align: right;">119</p> <p>1 were able to get a price better than nothing,</p> <p>2 better than throwing it away.</p> <p>3 BY MR. FAUCI:</p> <p>4 Q. What do you mean it was a distressed</p> <p>5 product?</p> <p>6 A. It was short code.</p> <p>7 Q. What does that mean?</p> <p>8 A. It means that it could expire.</p> <p>9 Q. What do you mean, "could expire"?</p> <p>10 A. Well, every product has a certain shelf</p> <p>11 life, and once it gets within -- typically once you</p> <p>12 get within 12 months, you can't sell it through</p> <p>13 wholesalers, which is why some of this document</p> <p>14 says that sales wouldn't go through wholesalers,</p> <p>15 because it takes them too long to get it through</p> <p>16 their distribution channel, and the product would</p> <p>17 expire before -- before it -- it reached the</p> <p>18 customer.</p> <p>19 Q. Can you look back at Exhibit 11. I'm</p> <p>20 looking at the second page of the exhibit, the</p> <p>21 paragraph starting, "I plan." This is Ms. Waterer</p> <p>22 writing.</p>	<p style="text-align: right;">121</p> <p>1 A. I'm not sure what that means.</p> <p>2 Q. A little bit further down, she writes,</p> <p>3 "Apria, MP Total Care, and Health Scripts will also</p> <p>4 be candidates for this substitution once they sign</p> <p>5 the 14 percent Loyalty Bonus Program Contract, as</p> <p>6 it has very specific definitions and penalties</p> <p>7 regarding diversion." You don't know what</p> <p>8 "diversion" means in that context?</p> <p>9 A. No.</p> <p>10 Q. Are you familiar with the difference --</p> <p>11 how is a sale to a wholesaler different than a sale</p> <p>12 to a customer such as a chain pharmacy?</p> <p>13 MS. RIVERA: Object to form and</p> <p>14 foundation.</p> <p>15 BY THE WITNESS:</p> <p>16 A. Chain pharmacies run their -- have their</p> <p>17 own warehouses, so they go -- they can go directly</p> <p>18 through their individual stores and move the</p> <p>19 product through quicker, whereas the wholesalers</p> <p>20 wouldn't.</p> <p>21 BY MR. FAUCI:</p> <p>22 Q. Isn't it also true that a sale to a</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)

February 26, 2009

Chicago, IL

36 (Pages 138 to 141)

138	140
<p>1 A. Yes.</p> <p>2 Q. Would this in large part be explained by</p> <p>3 its decision to dividend up \$320 million to its</p> <p>4 parent corporation?</p> <p>5 MS. RIVERA: Object to form.</p> <p>6 BY THE WITNESS:</p> <p>7 A. Yes.</p> <p>8 BY MR. FAUCI:</p> <p>9 Q. And do you see that Roxane's loans from</p> <p>10 affiliates have gone from zero to \$140 million?</p> <p>11 A. I see that.</p> <p>12 Q. Why at this -- why would Roxane dividend</p> <p>13 \$320 million to its parent only to take a loan from</p> <p>14 an affiliate of \$140 million?</p> <p>15 MS. RIVERA: Object to form.</p> <p>16 BY THE WITNESS:</p> <p>17 A. The loan would have been to help fund the</p> <p>18 \$320 million because they didn't have enough cash</p> <p>19 on hand.</p> <p>20 BY MR. FAUCI:</p> <p>21 Q. Well, let's look at Exhibit 20, which is</p> <p>22 Roxane's year-end statement for 2001. Do you see</p>	<p>1 A. When the dividend gets paid, you would</p> <p>2 credit retained earnings -- actually, debit</p> <p>3 retained earnings, because retained earnings is a</p> <p>4 credit balance account, and you'd have to debit</p> <p>5 something or credit something. So a credit has to</p> <p>6 be either out of cash or some other -- or take out</p> <p>7 a loan to increase your -- your loans payable to</p> <p>8 fund that payment.</p> <p>9 Q. Retained earnings are the amount of money</p> <p>10 that the corporation has earned over time, correct?</p> <p>11 MS. RIVERA: Object to form.</p> <p>12 BY THE WITNESS:</p> <p>13 A. Less any dividends that have been paid,</p> <p>14 yes.</p> <p>15 BY MR. FAUCI:</p> <p>16 Q. And so at the end of 2001, Roxane had</p> <p>17 \$358,522,000 in retained earnings; correct?</p> <p>18 A. Yes.</p> <p>19 Q. Why couldn't it have funded the dividend</p> <p>20 out of that?</p> <p>21 A. 'Cause it has to come from somewhere.</p> <p>22 Q. Doesn't it come from --</p>
139	141
<p>1 the retained earnings as of the end of 2001?</p> <p>2 MS. RIVERA: Hold on. 20? Okay.</p> <p>3 MR. FAUCI: Yes, we're on Exhibit 20.</p> <p>4 MS. RIVERA: Okay.</p> <p>5 BY THE WITNESS:</p> <p>6 A. Yes.</p> <p>7 BY MR. FAUCI:</p> <p>8 Q. And what are the retained earnings at the</p> <p>9 end of 2001?</p> <p>10 A. \$358,522,000.</p> <p>11 Q. And so Roxane could have funded the 320</p> <p>12 million dividend out of its own retained earnings,</p> <p>13 is that correct?</p> <p>14 MS. RIVERA: Object to form.</p> <p>15 BY THE WITNESS:</p> <p>16 A. But you have -- you have to pay the</p> <p>17 dividends with something, so some other account on</p> <p>18 the balance sheet would've had to change, they</p> <p>19 would've had -- have enough money to -- to fund</p> <p>20 that payment.</p> <p>21 BY MR. FAUCI:</p> <p>22 Q. I'm not following. Can you explain that?</p>	<p>1 A. 'Cause you would --</p> <p>2 Q. -- the retained --</p> <p>3 A. -- credit --</p> <p>4 Q. -- earnings?</p> <p>5 A. You would -- you would -- you'd have to</p> <p>6 debit retained earnings and credit something else</p> <p>7 on your balance sheet to pay that dividend. And</p> <p>8 typically that goes through the affiliate accounts.</p> <p>9 Q. And so in year-end 2002, turning back to</p> <p>10 Exhibit 22, Roxane shows loans from affiliates of</p> <p>11 \$140 million; is that correct?</p> <p>12 A. Yes.</p> <p>13 Q. Are those real loans?</p> <p>14 MS. RIVERA: Object to form.</p> <p>15 BY THE WITNESS:</p> <p>16 A. Real loans in what sense?</p> <p>17 BY MR. FAUCI:</p> <p>18 Q. Did Roxane actually borrow money from its</p> <p>19 affiliates?</p> <p>20 A. I'd have to say yes based -- 'cause this</p> <p>21 here.</p> <p>22 Q. And you testified earlier that they paid</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)

February 26, 2009

Chicago, IL

37 (Pages 142 to 145)

<p style="text-align: right;">142</p> <p>1 interest on those loans.</p> <p>2 A. Yes.</p> <p>3 Q. And so I'm trying to understand what this</p> <p>4 \$140 million entry is. Did -- does this reflect</p> <p>5 that at the end of 2002, Roxane had to borrow 140</p> <p>6 million doll -- Roxane chose to borrow \$140 million</p> <p>7 from its affiliates?</p> <p>8 A. Yes.</p> <p>9 Q. And it chose to -- and it paid interest</p> <p>10 on those loans?</p> <p>11 A. Believe so, yes.</p> <p>12 Q. And it did that -- and in the year prior</p> <p>13 to that, if you look at Exhibit 20, Roxane had no</p> <p>14 loans outstanding to affiliates; is that correct?</p> <p>15 A. Correct.</p> <p>16 Q. And so between 2001 and 2002, Roxane paid</p> <p>17 a dividend of \$320 million to its parent; correct?</p> <p>18 A. Correct.</p> <p>19 Q. And then took out loans of \$140 million</p> <p>20 from its affiliates, is that correct?</p> <p>21 A. Correct.</p> <p>22 Q. How was that beneficial to Roxane?</p>	<p style="text-align: right;">144</p> <p>1 three.</p> <p>2 BY MR. FAUCI:</p> <p>3 Q. Welcome back.</p> <p>4 A. Thank you.</p> <p>5 Q. I just have a few more questions. And I</p> <p>6 think we should start by what the court reporter</p> <p>7 has marked as Exhibit 23.</p> <p>8 (WHEREUPON, a certain document was</p> <p>9 marked Exhibit McIntyre 023, for identification.)</p> <p>10 BY THE WITNESS:</p> <p>11 A. Thank you.</p> <p>12 BY MR. FAUCI:</p> <p>13 Q. This is another in the series of</p> <p>14 documents, which is a Roxane Laboratories Unanimous</p> <p>15 Written Consent of Directors, and this appears to</p> <p>16 contain the closing -- year-end closing for 2003,</p> <p>17 is that correct?</p> <p>18 A. That's correct.</p> <p>19 Q. I'm going to ask you to turn to the</p> <p>20 balance sheet. It's a number of pages in. It's</p> <p>21 the page Bates labeled BOEH04600471. And do you</p> <p>22 see that the retained earnings for Roxane at the</p>
<p style="text-align: right;">143</p> <p>1 MS. RIVERA: Object to form.</p> <p>2 BY THE WITNESS:</p> <p>3 A. I'm not sure how to -- how to answer</p> <p>4 that.</p> <p>5 MS. RIVERA: Do you need him to re --</p> <p>6 give you more information or rephrase it, or --</p> <p>7 THE WITNESS: No.</p> <p>8 MS. RIVERA: -- are you just thinking?</p> <p>9 THE WITNESS: I'm thinking.</p> <p>10 MS. RIVERA: Okay.</p> <p>11 BY THE WITNESS:</p> <p>12 A. I -- I don't know how to answer that.</p> <p>13 BY MR. FAUCI:</p> <p>14 Q. Can I show you exhibit --</p> <p>15 MR. FAUCI: Why don't we take a break.</p> <p>16 We only have a couple minutes on the tape.</p> <p>17 MS. RIVERA: Oh, okay.</p> <p>18 THE VIDEOGRAPHER: We are off the record</p> <p>19 at 12:24 p.m. with the end of tape number two.</p> <p>20 (WHEREUPON, a recess was had.)</p> <p>21 THE VIDEOGRAPHER: We are back on the</p> <p>22 record at 1:15 p.m. with the start of tape number</p>	<p style="text-align: right;">145</p> <p>1 end of 2003 were \$65 million?</p> <p>2 A. Yes.</p> <p>3 Q. Can you turn the page. This is -- says,</p> <p>4 "Roxane Laboratories Statement of Financial</p> <p>5 Position, Actual 2003 versus Budget 2003." Do you</p> <p>6 see that?</p> <p>7 A. Yes.</p> <p>8 Q. Look at the very bottom. Can you read</p> <p>9 what it says under "Retained Earnings"?</p> <p>10 A. "Retained earnings was \$241.9 million</p> <p>11 below budget. This reduction is the result of</p> <p>12 increased dividend payments made at year-end 2002."</p> <p>13 Q. And then can you read the section "Loans</p> <p>14 From Affiliates" directly above it.</p> <p>15 A. "Loans from affiliates were 62.3 million</p> <p>16 above budget. The reason for the increase is the</p> <p>17 interim dividend payment made in 2002. For the</p> <p>18 Budget, the planned dividend was 75 million versus</p> <p>19 the actual payment of 320 million."</p> <p>20 Q. What does it -- what does it mean that</p> <p>21 it's an "interim dividend payment"?</p> <p>22 A. I'm not sure what the reference to</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)

February 26, 2009

Chicago, IL

41 (Pages 158 to 161)

<p style="text-align: right;">158</p> <p>1 A. My understanding is Roxane did.</p> <p>2 Q. Was the trademark for that drug ever</p> <p>3 owned by BIPI?</p> <p>4 A. Not to my knowledge.</p> <p>5 Q. If I ask you the same question for</p> <p>6 Roxicodone --</p> <p>7 A. Yes.</p> <p>8 Q. -- was that a drug that was marketed by</p> <p>9 Roxane prior to 2001?</p> <p>10 A. Yes.</p> <p>11 Q. Did Roxane own the trademark for that</p> <p>12 drug?</p> <p>13 A. Best of my knowledge, yes.</p> <p>14 Q. Let me ask you a question about the</p> <p>15 distribution agreement for Viramune. Do you know</p> <p>16 when, if at all, that distribution agreement ended?</p> <p>17 MS. RIVERA: Do you mean the licensing</p> <p>18 agreement, Ros?</p> <p>19 MS. POLLACK: Sorry, the licensing</p> <p>20 agreement.</p> <p>21 BY THE WITNESS:</p> <p>22 A. The licensing agreement ended in 2001.</p>	<p style="text-align: right;">160</p> <p>1 term -- the length -- by "term," you mean length of</p> <p>2 term, I assume.</p> <p>3 BY MS. POLLACK:</p> <p>4 Q. Right. Length of time.</p> <p>5 A. I -- I don't recall.</p> <p>6 Q. Do you recall if Roxane paid any fee to</p> <p>7 terminate that license agreement in 2001?</p> <p>8 A. No, but they -- they would just have</p> <p>9 discontinued paying the royalty.</p> <p>10 Q. Well, Mr. Fauci marked a number of year-</p> <p>11 end statements and balance sheets earlier today.</p> <p>12 Are you familiar with the fact that on occasion</p> <p>13 Roxane made short-term advances to affiliates?</p> <p>14 A. Yes.</p> <p>15 Q. Okay. When would those kinds of advances</p> <p>16 be made?</p> <p>17 A. Well, just similar to the short-term</p> <p>18 loans, all of that, either advances or loans,</p> <p>19 they're all part of the cash pooling process that</p> <p>20 takes place with all the activity that goes on</p> <p>21 between the companies.</p> <p>22 Q. When there was a short-term advance to an</p>
<p style="text-align: right;">159</p> <p>1 BY MS. POLLACK:</p> <p>2 Q. And why was that?</p> <p>3 A. 2001 was the year that Roxane divested</p> <p>4 itself of the pain medication products, which</p> <p>5 included the Roxicodone and the Oramorph we just</p> <p>6 discussed. As a result of that divestment, the</p> <p>7 sales force that marketed those products was -- was</p> <p>8 eliminated; and as a result, BIPI took the product</p> <p>9 back. And at the same time, BIPI had a -- another</p> <p>10 aged related drug in development. And with that</p> <p>11 product coming online soon, they wanted -- they had</p> <p>12 the combination of those two A drugs that they</p> <p>13 would be marketing.</p> <p>14 Q. What was the term of the license</p> <p>15 agreement that Roxane had for Viramune; in other</p> <p>16 words, was it yearly, monthly?</p> <p>17 A. Viramune license agreement.</p> <p>18 MS. RIVERA: Object to form, beyond the</p> <p>19 scope of the notice.</p> <p>20 If you know.</p> <p>21 BY THE WITNESS:</p> <p>22 A. Yeah, I don't -- I don't recall what the</p>	<p style="text-align: right;">161</p> <p>1 affiliate made by Roxane, would there be any</p> <p>2 documentation relating to that advance?</p> <p>3 A. It would be in -- in the internal</p> <p>4 accounting records.</p> <p>5 Q. Would there be a note signed?</p> <p>6 A. I don't know if there'd be a note signed.</p> <p>7 Q. Would -- would there be any kind of</p> <p>8 letter agreement or contract re -- relating to that</p> <p>9 advance?</p> <p>10 A. I don't know.</p> <p>11 Q. Would there be interest associated with</p> <p>12 the short-term advance?</p> <p>13 A. Yes, there should be, based on that LIBOR</p> <p>14 rate we discussed earlier, on the affiliate loan.</p> <p>15 Q. When you say, "there should be," were</p> <p>16 there, in fact, interest terms associated with the</p> <p>17 short-term --</p> <p>18 A. Yes --</p> <p>19 Q. -- investment --</p> <p>20 A. -- there were interest terms.</p> <p>21 Q. And would the interest be paid by a</p> <p>22 bookkeeping line item?</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com



Roxane Laboratories, Inc (James F. McIntyre)

February 26, 2009

Chicago, IL

42 (Pages 162 to 165)

162	164
<p>1 A. If -- well, what do you mean by</p> <p>2 "bookkeeping line item" --</p> <p>3 Q. Yeah --</p> <p>4 A. -- please?</p> <p>5 Q. -- let me -- let me rephrase that.</p> <p>6 How would the interest payments be made?</p> <p>7 A. It would be made as part of the -- the</p> <p>8 accounting records.</p> <p>9 Q. Would actual cash transfer from one</p> <p>10 entity to another?</p> <p>11 A. Again, that's all part of the -- all of</p> <p>12 these loans and things are all part of the cash</p> <p>13 pooling and the -- and the -- and the netting of</p> <p>14 the -- the affiliate transactions that take place.</p> <p>15 Q. Could you describe what you mean by "the</p> <p>16 cash pooling."</p> <p>17 A. The -- Boehringer uses what's called a</p> <p>18 zero balance cash, so every -- every legal entity</p> <p>19 has their own bank account, so to speak. But at</p> <p>20 the end of the day, the -- the bank where all these</p> <p>21 accounts are just kind of sweeps all that cash into</p> <p>22 one pool. And then they still record the quant --</p>	<p>1 money in the pool was swept out daily and sent to</p> <p>2 Germany, you wouldn't have any reason to disagree</p> <p>3 with that?</p> <p>4 A. I wouldn't, no.</p> <p>5 Q. Can you take a look at Exhibit 8, that</p> <p>6 Mr. Fauci asked you about earlier.</p> <p>7 A. Yes.</p> <p>8 Q. And on page 23, it states that the "MDI</p> <p>9 and SM standard based upon bulk material being</p> <p>10 transferred to RLI at zero cost. This assumption</p> <p>11 is no longer valid."</p> <p>12 A. Yes.</p> <p>13 Q. Yes, you read that. Does that indicate</p> <p>14 to you that prior to a change being reflected in</p> <p>15 the budget, the cost of goods sold were being</p> <p>16 reflected at a zero cost --</p> <p>17 MS. RIVERA: Object to form.</p> <p>18 BY MS. POLLACK:</p> <p>19 Q. -- for the MDI and the SM products?</p> <p>20 A. And I think I testified earlier that I</p> <p>21 was unaware what the -- what the accounting change</p> <p>22 meant, so I couldn't speak to this.</p>
163	165
<p>1 the amount of cash by legal entities, but that --</p> <p>2 they pool it all together so that they can invest</p> <p>3 that money to earn interest.</p> <p>4 Q. Is that --</p> <p>5 A. It's much -- much --</p> <p>6 Q. -- money invested on behalf of BIC?</p> <p>7 A. It's invested on behalf of all the legal</p> <p>8 entities.</p> <p>9 Q. Is the money swept out of that pool daily</p> <p>10 and -- and sent out of the country?</p> <p>11 A. It's swept out of the pool daily. I</p> <p>12 don't know that it's swept -- or sent out of the</p> <p>13 country, no.</p> <p>14 Q. If Mr. --</p> <p>15 A. It remains --</p> <p>16 Q. -- Tetzner --</p> <p>17 A. -- in -- it remains in BIC's -- it</p> <p>18 remains in BIC's account or in fund with all the --</p> <p>19 with all the individual legal entities. It's kept</p> <p>20 track of by the legal entity account numbers, but</p> <p>21 it's all in one pool.</p> <p>22 Q. But if Mr. Tetzner had testified that the</p>	<p>1 Q. It doesn't say to you that whatever the</p> <p>2 accounting change meant, it was a change from zero</p> <p>3 to something else?</p> <p>4 MS. RIVERA: Object to form.</p> <p>5 BY THE WITNESS:</p> <p>6 A. I -- I see that's what it says, but I</p> <p>7 can't speak to it.</p> <p>8 BY MS. POLLACK:</p> <p>9 Q. Now, this statement also indicates that</p> <p>10 there's something called the self medication</p> <p>11 product.</p> <p>12 MS. RIVERA: Where are you, Ros?</p> <p>13 MS. POLLACK: Right on that same page on</p> <p>14 the --</p> <p>15 MS. RIVERA: Oh, okay.</p> <p>16 MS. POLLACK: -- standard cost of goods</p> <p>17 sold, self medication product.</p> <p>18 MS. RIVERA: I got it.</p> <p>19 MS. POLLACK: You see that?</p> <p>20 MS. RIVERA: Yep.</p> <p>21 Sorry, Jim.</p> <p>22 BY MS. POLLACK:</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)  
Chicago, IL

February 26, 2009

45 (Pages 174 to 177)

<p style="text-align: right;">174</p> <p>1 of one of the options, the preferred option.</p> <p>2 Q. And the third bullet says, "Moves</p> <p>3 employees under the legal entity to which they</p> <p>4 report;" is that correct?</p> <p>5 A. That's correct.</p> <p>6 Q. So there were people who were employed by</p> <p>7 one company but reporting to another, is that what</p> <p>8 that means?</p> <p>9 A. Yes, specifically the manufacturing</p> <p>10 situation we just discussed.</p> <p>11 Q. Are you talking about the Combivent?</p> <p>12 A. Yes.</p> <p>13 Q. Well, weren't these people prior to 19 --</p> <p>14 I'm sorry, prior to 2005, who were manufacturing</p> <p>15 Combivent, BIPI employees?</p> <p>16 A. That's correct.</p> <p>17 Q. And that prior to 2005, Combivent was a</p> <p>18 BIPI drug; right?</p> <p>19 A. That's correct. It still is.</p> <p>20 Q. So why would you have to move them under</p> <p>21 the legal entity which -- to which they report when</p> <p>22 they were already under the legal entity to which</p>	<p style="text-align: right;">176</p> <p>1 people.</p> <p>2 Q. The next bullet point, there's a line,</p> <p>3 the oper -- the organization with the actual</p> <p>4 businesses, what's meant by that?</p> <p>5 A. Again, given that the overriding driver</p> <p>6 for the separation or for the reorganization was to</p> <p>7 separate the two legal entities or to separate the</p> <p>8 two businesses that were part of the Roxane legal</p> <p>9 entity, we wanted to get the organization aligned</p> <p>10 so that the manufacturing people were all part of</p> <p>11 the manufacturing organization and the sales and</p> <p>12 marketing people were part of the sales</p> <p>13 organization, so that those two businesses could be</p> <p>14 judged and -- their performance could be judged</p> <p>15 independently.</p> <p>16 Q. And what does the last bullet point say</p> <p>17 under "the advantages of the new legal entity"?</p> <p>18 A. At the -- way down at the bottom, the</p> <p>19 "allows for separation of liability"?</p> <p>20 Q. Yes. Could you read that into the</p> <p>21 record, please.</p> <p>22 A. "Allows for separation of liability for</p>
<p style="text-align: right;">175</p> <p>1 they reported?</p> <p>2 A. Because -- because the -- the Roxane</p> <p>3 manufacturing people were responsible for that</p> <p>4 manufacturing line. And those manufacturing people</p> <p>5 in BIPI were reporting to people in Roxane, or BIRI</p> <p>6 after the 2005 split. And that's why this comment</p> <p>7 says move people -- move people -- employees under</p> <p>8 the legal entity to which they report. That was</p> <p>9 one of the anomalies of the -- of our organization,</p> <p>10 that the 2005 organization wanted to -- wanted to</p> <p>11 correct. Remember, the overriding driver of the</p> <p>12 reorganization was to separate the two businesses</p> <p>13 that were part of the Roxane business prior to 2005</p> <p>14 and part of the Roxane legal entity.</p> <p>15 Q. But the Combivent was part of BIPI prior</p> <p>16 to 2005?</p> <p>17 A. That's correct, the manufacturing was,</p> <p>18 yes, but managed --</p> <p>19 Q. And --</p> <p>20 A. -- by BIRI people.</p> <p>21 Q. I'm sorry, I didn't hear that.</p> <p>22 A. But managed by Roxane manufacturing</p>	<p style="text-align: right;">177</p> <p>1 Marketing and Sales of Multisource and</p> <p>2 manufacturing of Multisource products." The intent</p> <p>3 of that bullet is to -- is to -- we're really just</p> <p>4 trying to align liability with the business, so if</p> <p>5 manufacturing had a -- if there was a manufacturing</p> <p>6 liability, the manufacturing legal entity was --</p> <p>7 was accountable for that. So we're just trying to</p> <p>8 align liability with the business.</p> <p>9 Q. Whereas, prior to that time, any of those</p> <p>10 liabilities would have been part of Roxane</p> <p>11 Laboratories, Inc., which had both the</p> <p>12 manufacturing and the sales for the multisource</p> <p>13 product; is that correct?</p> <p>14 A. Excuse -- I -- I didn't hear your entire</p> <p>15 question, so if you could repeat it, please.</p> <p>16 MS. POLLACK: Could you read it back?</p> <p>17 Did you get it --</p> <p>18 THE COURT REPORTER: You trailed off --</p> <p>19 MS. POLLACK: -- the court reporter?</p> <p>20 THE COURT REPORTER: -- at the end for</p> <p>21 me, too.</p> <p>22 BY THE WITNESS:</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com



Roxane Laboratories, Inc (James F. McIntyre)

February 26, 2009

Chicago, IL

46 (Pages 178 to 181)

<p style="text-align: right;">178</p> <p>1 A. She didn't get it either.</p> <p>2 THE COURT REPORTER: Prior to that time -</p> <p>3 -</p> <p>4 BY MS. POLLACK:</p> <p>5 Q. Sure. I'm sorry. Let me try again.</p> <p>6 So prior to this time, however, the</p> <p>7 liabilities for the Roxane manufacturing operation</p> <p>8 and the Roxane sales and marketing organization</p> <p>9 would have been liabilities of Roxane Laboratories,</p> <p>10 Inc.?</p> <p>11 A. That's correct.</p> <p>12 MS. POLLACK: I have nothing further.</p> <p>13 MS. RIVERA: Anybody else on the phone?</p> <p>14 MR. WINGET-HERNANDEZ: Yeah, I'm here,</p> <p>15 but I'm reserving my questioning.</p> <p>16 MS. RIVERA: Okay. Can we take like a</p> <p>17 15, 20 minute break so I can get my ducks in a row,</p> <p>18 and then we can come back?</p> <p>19 MR. FAUCI: Thank you.</p> <p>20 THE VIDEOGRAPHER: We are off the record</p> <p>21 at 1:58 p.m.</p> <p>22 (WHEREUPON, a recess was had.)</p>	<p style="text-align: right;">180</p> <p>1 Q. Okay. If you looked at Exhibit 10, which</p> <p>2 is the October 23, 1996, interoffice memo from Mr.</p> <p>3 Spitalli, do you see that?</p> <p>4 A. Yes.</p> <p>5 Q. Okay. I just wanted to direct your</p> <p>6 attention in the third paragraph, the last</p> <p>7 sentence, do you see where it says, "We are able to</p> <p>8 fill selected orders because the BIPI's Atrovent</p> <p>9 Solution inventory is, quote, "distressed" due to</p> <p>10 dating and lowering sales volumes." Do you see</p> <p>11 that?</p> <p>12 A. Yes, I see that.</p> <p>13 Q. Okay. Is that consistent with your</p> <p>14 testimony that you believe that BIPI was willing to</p> <p>15 engage in this project in part because its</p> <p>16 inventory was short dated?</p> <p>17 MR. FAUCI: Objection to the form.</p> <p>18 BY THE WITNESS:</p> <p>19 A. Yes.</p> <p>20 BY MS. RIVERA:</p> <p>21 Q. Okay. And if BIPI was unable to sell</p> <p>22 this product through the substitution program for</p>
<p style="text-align: right;">179</p> <p>1 (WHEREUPON, MR. ANDERSON</p> <p>2 disconnected from telephonic communication.)</p> <p>3 THE VIDEOGRAPHER: We are back on the</p> <p>4 record at 2:30 p.m.</p> <p>5</p> <p>6 EXAMINATION</p> <p>7 BY MS. RIVERA:</p> <p>8 Q. Good afternoon, Mr. McIntyre. I just</p> <p>9 wanted to take a few minutes to follow-up on a few</p> <p>10 things that you discussed with Mr. Fauci and</p> <p>11 clarify a few things.</p> <p>12 Do you recall a discussion with Mr. Fauci</p> <p>13 about a time period in 1996 where brand name</p> <p>14 Atrovent was substituted for Roxane's Ipratropium</p> <p>15 Bromide?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. And I wanted -- wondered if you</p> <p>18 could look in your stack back at Exhibits 10 and</p> <p>19 11. Do you have them? Keep going. There --</p> <p>20 A. They're probably --</p> <p>21 Q. -- they are.</p> <p>22 A. -- further down. Here's 10 and 11.</p>	<p style="text-align: right;">181</p> <p>1 Roxane's Ipratropium Bromide, what was likely to</p> <p>2 happen to that inventory that was distressed?</p> <p>3 A. Expired product would have been</p> <p>4 destroyed.</p> <p>5 Q. Okay. And if the product had been</p> <p>6 destroyed, would BIPI make any money on that</p> <p>7 product?</p> <p>8 A. No.</p> <p>9 Q. Okay. And, in fact, in two paragraphs</p> <p>10 down, there's a sentence from Mr. Spitalli who</p> <p>11 says, "This is a win-win situation."</p> <p>12 A. I see that.</p> <p>13 Q. Okay. Is that consistent with your</p> <p>14 understanding of -- of the situation for BIPI and</p> <p>15 Roxane?</p> <p>16 MR. FAUCI: Objection to form.</p> <p>17 BY THE WITNESS:</p> <p>18 A. Yes.</p> <p>19 BY MS. RIVERA:</p> <p>20 Q. Okay. And then if you would just look at</p> <p>21 Exhibit 11, the paragraph at the bottom on the</p> <p>22 first page, where it says, "Mike." It says, "Mike</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)

February 26, 2009

Chicago, IL

48 (Pages 186 to 189)

186	188
<p>1 A. I confirmed that with Judy Waterer.</p> <p>2 BY MS. RIVERA:</p> <p>3 Q. Okay. There was also some discussion</p> <p>4 about some commitment agreements and rebates that</p> <p>5 were paid. Do you recall that discussion?</p> <p>6 A. Yes.</p> <p>7 Q. Okay. It's in reference to Exhibit 17.</p> <p>8 MS. RIVERA: Oh, actually -- well, can</p> <p>9 you mark --</p> <p>10 MR. FAUCI: I'm thinking it's on 17.</p> <p>11 MS. RIVERA: It's what?</p> <p>12 MR. FAUCI: Nothing.</p> <p>13 MS. RIVERA: Oh, you know what --</p> <p>14 BY THE WITNESS:</p> <p>15 A. 13.</p> <p>16 BY MS. RIVERA:</p> <p>17 Q. Yeah, it's -- I'm looking at -- yeah, and</p> <p>18 set that aside for one minute. I wanted to mark</p> <p>19 one more document with you on the last issue.</p> <p>20 (WHEREUPON, a certain document was</p> <p>21 marked Exhibit McIntyre 026, for identification.)</p> <p>22 BY MS. RIVERA:</p>	<p>1 Q. Is that --</p> <p>2 A. Yes.</p> <p>3 Q. -- referring to the substitution that we</p> <p>4 were discussing?</p> <p>5 A. Yes.</p> <p>6 Q. Okay. He says, "I have listed below the</p> <p>7 process I -- as I understand it, which was</p> <p>8 implemented as of last Friday, October 25th." Can</p> <p>9 you read through that, and tell me whether that</p> <p>10 supports your testimony as to whether BIPI booked</p> <p>11 these sales, and there were no intra-company sales.</p> <p>12 MR. FAUCI: Objection to the form.</p> <p>13 BY THE WITNESS:</p> <p>14 A. I see in point three that Judy Waterer is</p> <p>15 going to communicate to the -- the BI Services</p> <p>16 Center which orders will be processed as BIPI</p> <p>17 invoices.</p> <p>18 BY MS. RIVERA:</p> <p>19 Q. And what does that mean?</p> <p>20 A. So that confirms -- to me, that confirms</p> <p>21 that BIPI was gonna book the sale for the -- that</p> <p>22 entry.</p>
187	189
<p>1 Q. Okay. The court reporter's handed you</p> <p>2 what has been marked as Exhibit 26.</p> <p>3 MS. RIVERA: And for the record, the top</p> <p>4 -- it's an e-mail chain, the top e-mail is from</p> <p>5 Judy Waterer, dated November 4, 1996.</p> <p>6 BY MS. RIVERA:</p> <p>7 Q. Do you see that?</p> <p>8 A. Yes, I do.</p> <p>9 Q. Okay. If you would look to what looks</p> <p>10 like the third e-mail on this page from John Swartz</p> <p>11 to Ed Tupa.</p> <p>12 A. Yes, I have it.</p> <p>13 Q. Okay. And that's dated Thursday, October</p> <p>14 31st?</p> <p>15 A. Yes.</p> <p>16 Q. Okay. If you could take a look at this,</p> <p>17 it says, "This is regarding the RLI sales of</p> <p>18 Ipratropium that will be filled with BIPI's</p> <p>19 Atrovent." That's referring to the substitution</p> <p>20 that we were discussing?</p> <p>21 MR. FAUCI: Objection to the form.</p> <p>22 BY MS. RIVERA:</p>	<p>1 Q. Okay. If Roxane had booked the sale,</p> <p>2 what would you expect that to be?</p> <p>3 A. It would have referenced Roxane invoices.</p> <p>4 Q. Okay. Okay. Okay. Now moving on to the</p> <p>5 bundling and rebate agreements. I believe you were</p> <p>6 asked who booked and paid for the rebates on BIPI</p> <p>7 products that are a part of this -- these</p> <p>8 commitment and loyalty agreements. Do you recall</p> <p>9 that?</p> <p>10 A. Yes, I do.</p> <p>11 Q. Okay.</p> <p>12 (WHEREUPON, a certain document was</p> <p>13 marked Exhibit McIntyre 027, for identification.)</p> <p>14 BY MS. RIVERA:</p> <p>15 Q. What number is that? I'm sorry.</p> <p>16 A. 27.</p> <p>17 Q. Thank you. Okay. You've been handed a</p> <p>18 document, which is dated -- I'm sorry, which has</p> <p>19 been marked Exhibit 27. And in the first paragraph</p> <p>20 there, it says, "After discussing the one percent</p> <p>21 rebate for the branded product and in doing an</p> <p>22 analysis," et cetera, "Shelly and I agree that the</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)  
Chicago, IL

February 26, 2009

49 (Pages 190 to 193)

<p style="text-align: right;">190</p> <p>1 one percent rebate should be charged against the</p> <p>2 Roxane P&amp;L."</p> <p>3 What does that indicate to you in terms</p> <p>4 of how rebates for BIPI products that were part of</p> <p>5 Roxane loyalty or commitment agreements were</p> <p>6 booked?</p> <p>7 A. They're going to be paid for by Roxane.</p> <p>8 Q. Okay. And were you able to do any other</p> <p>9 research to confirm that this is the way it worked</p> <p>10 for -- for all of these various agreements?</p> <p>11 A. Yes, I confirmed this with Judy Waterer.</p> <p>12 Q. Okay. So BIPI was not paying the rebate</p> <p>13 even though the rebate was based on BIPI products?</p> <p>14 A. That's correct.</p> <p>15 MR. FAUCI: Objection to form.</p> <p>16 BY MS. RIVERA:</p> <p>17 Q. Okay. You were also asked some questions</p> <p>18 about dividend payments from Roxane to BIC. Do you</p> <p>19 recall that discussion?</p> <p>20 A. Yes.</p> <p>21 Q. Okay. What is the purpose of dividend</p> <p>22 payments?</p>	<p style="text-align: right;">192</p> <p>1 A. Yes, I did.</p> <p>2 Q. Okay. Based on your knowledge of</p> <p>3 Roxane's financial condition and the -- the payment</p> <p>4 of these dividends, do you believe that any of the</p> <p>5 dividend payments that were made by Roxane to BIC</p> <p>6 during the relevant time frame left Roxane</p> <p>7 undercapitalized?</p> <p>8 MR. FAUCI: Objection --</p> <p>9 MS. POLLACK: Objection --</p> <p>10 MR. FAUCI: -- to the form.</p> <p>11 BY THE WITNESS:</p> <p>12 A. No.</p> <p>13 BY MS. RIVERA:</p> <p>14 Q. Okay. And why not?</p> <p>15 A. 'Cause --</p> <p>16 MR. FAUCI: Objection to the form.</p> <p>17 BY THE WITNESS:</p> <p>18 A. They continued to have positive retained</p> <p>19 earnings, and they also had positive working</p> <p>20 capitals to fund their day-to-day operations.</p> <p>21 BY MS. RIVERA:</p> <p>22 Q. Okay. And during the time that you were</p>
<p style="text-align: right;">191</p> <p>1 A. Typically it's to return part of the</p> <p>2 investment to the parent company.</p> <p>3 Q. Okay. And is this a normal procedure</p> <p>4 between subsidiary and parent companies?</p> <p>5 A. Yes.</p> <p>6 MR. FAUCI: Objection to form.</p> <p>7 BY THE WITNESS:</p> <p>8 A. Yes.</p> <p>9 BY MS. RIVERA:</p> <p>10 Q. Okay. Based on your -- well, let me ask</p> <p>11 you this: Based on your -- sorry, strike that</p> <p>12 again.</p> <p>13 You were a member of Roxane's finance</p> <p>14 department from 1996 to 2005, is that correct?</p> <p>15 A. That's correct.</p> <p>16 Q. Okay. And as a member of Roxane's</p> <p>17 finance department, were you familiar with Roxane's</p> <p>18 financial condition during that time frame?</p> <p>19 A. Yes.</p> <p>20 Q. Okay. And in preparation for this</p> <p>21 deposition, did you review Roxane's financial</p> <p>22 statements over time?</p>	<p style="text-align: right;">193</p> <p>1 in Roxane's financial department, do you know if</p> <p>2 Roxane -- you know, during the entire time they --</p> <p>3 that you were in Roxane's financial department, if</p> <p>4 you have -- if Roxane had sufficient working</p> <p>5 capital to fund its day-to-day operations?</p> <p>6 MR. FAUCI: Objection to the form.</p> <p>7 BY THE WITNESS:</p> <p>8 A. Yes.</p> <p>9 BY MS. RIVERA:</p> <p>10 Q. Okay. Was there ever a time when Roxane</p> <p>11 was unable to pay its day-to-day obligations during</p> <p>12 this time period?</p> <p>13 A. No.</p> <p>14 MR. FAUCI: Objection to the form.</p> <p>15 BY MS. RIVERA:</p> <p>16 Q. Okay.</p> <p>17 MS. RIVERA: What's your objection?</p> <p>18 MR. FAUCI: Can you repeat the question?</p> <p>19 THE COURT REPORTER: "Question: Okay" --</p> <p>20 MR. FAUCI: I can read it.</p> <p>21 The objection is that I'm very unclear</p> <p>22 what you mean by the phrase "day-to-day</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)

February 26, 2009

Chicago, IL

50 (Pages 194 to 197)

<p style="text-align: right;">194</p> <p>1 operations," so I would say it's vagueness.</p> <p>2 MS. RIVERA: Okay.</p> <p>3 BY MS. RIVERA:</p> <p>4 Q. Are you aware -- let me just try to fix</p> <p>5 it, even though I disagree with the -- do you</p> <p>6 understand what I mean by "day-to-day operations,"</p> <p>7 Mr. McIntyre?</p> <p>8 A. Yes.</p> <p>9 Q. And how would you describe the day-to-day</p> <p>10 operations of Roxane?</p> <p>11 A. To be able to pay our bills, pay our --</p> <p>12 our vendors, pay our employees, purchase --</p> <p>13 purchase ingredients, raw materials for -- for</p> <p>14 manufacturing.</p> <p>15 Q. Okay. Okay. So let me just ask it</p> <p>16 again. Based on that day-to-day -- based on that</p> <p>17 definition of -- of day-to-day business, do you</p> <p>18 believe based on your familiarity with Roxane's</p> <p>19 financial con -- condition and your review of</p> <p>20 Roxane's financial statements that Roxane had</p> <p>21 sufficient capital to pay its day-to-day expenses -</p> <p>22 -</p>	<p style="text-align: right;">196</p> <p>1 A. Yes, there is a general rule, guideline</p> <p>2 from our corporate parent, that the debt to equity</p> <p>3 ratio shouldn't exceed a certain amount. If it --</p> <p>4 if it exceeded a certain amount, then dividends</p> <p>5 would not be paid.</p> <p>6 BY MS. RIVERA:</p> <p>7 Q. Okay. Then there were some questions</p> <p>8 specific to a dividend that was paid in 2002 from</p> <p>9 Roxane to BIC, I think, in the amount of \$320</p> <p>10 million. Do you remember that?</p> <p>11 A. Yes, I do.</p> <p>12 Q. Okay. Were you able to determine why</p> <p>13 that dividend payment was larger than dividend</p> <p>14 payments that had been paid in the past, that Mr.</p> <p>15 Fauci also referred you to?</p> <p>16 A. Yes. There was a couple of things that</p> <p>17 happened in the prior year that -- that resulted in</p> <p>18 larger -- more income for Roxane. First, we sold</p> <p>19 the palliative care business, so the income was --</p> <p>20 the income that Roxane reported in 2001 was a lot</p> <p>21 larger than had been expected; two, there were some</p> <p>22 tax issues pending that allowed us -- that was</p>
<p style="text-align: right;">195</p> <p>1 MS. POLLACK: Objection as to form.</p> <p>2 MS. RIVERA: I'm not done yet.</p> <p>3 MS. POLLACK: Sorry.</p> <p>4 MS. RIVERA: It's okay.</p> <p>5 BY MS. RIVERA:</p> <p>6 Q. To pay its day-to-day expenses and fund</p> <p>7 its day-to-day operations from 1996 through 2005?</p> <p>8 MS. POLLACK: Objection to form.</p> <p>9 BY THE WITNESS:</p> <p>10 A. Yes.</p> <p>11 BY MS. RIVERA:</p> <p>12 Q. Okay. And this is your view even though</p> <p>13 at certain points of time Roxane paid dividends to</p> <p>14 its parent comp -- corporation?</p> <p>15 A. Yes.</p> <p>16 Q. Okay. Do you have any understanding</p> <p>17 whether the capitalization and Roxane's ability to</p> <p>18 pay and fund its -- its day-to-day operations was</p> <p>19 taken into account when determining whether</p> <p>20 dividends should be paid to -- to BIC or not?</p> <p>21 MR. FAUCI: Objection.</p> <p>22 BY THE WITNESS:</p>	<p style="text-align: right;">197</p> <p>1 gonna allow us to pay some additional dividends;</p> <p>2 and, three, we hadn't paid a dividend in -- since</p> <p>3 2000, so this -- the payment in 2002 was -- was a</p> <p>4 catch-up for a two-year period.</p> <p>5 Q. Okay.</p> <p>6 (WHEREUPON, a certain document was</p> <p>7 marked Exhibit McIntyre 028, for identification.)</p> <p>8 BY MS. RIVERA:</p> <p>9 Q. Okay. Okay. The court reporter has</p> <p>10 handed you what's been marked as Exhibit 28. Can</p> <p>11 you tell me what this is?</p> <p>12 A. This is the 2001 year-end financial</p> <p>13 commentary or commentary to the financial</p> <p>14 statements.</p> <p>15 Q. Okay. Are these documents that Roxane</p> <p>16 generates in its normal course of business, or did</p> <p>17 at this point in time?</p> <p>18 A. Yes.</p> <p>19 Q. And you're familiar with these kinds of</p> <p>20 documents?</p> <p>21 A. Yes.</p> <p>22 Q. Okay.</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

Roxane Laboratories, Inc (James F. McIntyre)

February 26, 2009

Chicago, IL

51 (Pages 198 to 201)

<p style="text-align: right;">198</p> <p>1 MR. FAUCI: Objection to form.</p> <p>2 BY MS. RIVERA:</p> <p>3 Q. If you would turn to the page that ends -</p> <p>4 - if you see the BOEH numbers there --</p> <p>5 A. Uh-huh.</p> <p>6 Q. -- that ends in 452, it's a -- it's right</p> <p>7 -- it's a commentary right after the income</p> <p>8 statement.</p> <p>9 A. Total company income statement, right?</p> <p>10 Q. Yes.</p> <p>11 A. Yes, okay. I have it.</p> <p>12 Q. Okay. And it says, "2001 actual income</p> <p>13 is 175 million," and it says under that, attribute</p> <p>14 -- "Attributable to the Elan deal for the purchase</p> <p>15 of pain/palliative care products line." Can you</p> <p>16 tell me what that means in terms of how much Roxane</p> <p>17 was paid for its divestment of the Elan palliative</p> <p>18 care line?</p> <p>19 A. That -- well, this -- this would</p> <p>20 represent the amount of income that they were made</p> <p>21 -- made on this sale of the -- the line.</p> <p>22 Q. Okay. So is that the same as saying that</p>	<p style="text-align: right;">200</p> <p>1 MR. FAUCI: Objection --</p> <p>2 BY THE WITNESS:</p> <p>3 A. -- correct.</p> <p>4 MR. FAUCI: -- to the form.</p> <p>5 BY MS. RIVERA:</p> <p>6 Q. Okay.</p> <p>7 A. That is correct.</p> <p>8 Q. Were you able to determine, Mr. McIntyre,</p> <p>9 whether the payment of the \$320 million dividend in</p> <p>10 2002 had anything to do with pending subpoenas or</p> <p>11 litigation at Roxane?</p> <p>12 MR. FAUCI: Objection to the form.</p> <p>13 BY THE WITNESS:</p> <p>14 A. Yes, I was able to determine from</p> <p>15 conversations with Frank Palmer that it had nothing</p> <p>16 to do with any litigation.</p> <p>17 BY MS. RIVERA:</p> <p>18 Q. Okay. Okay. Just a few general</p> <p>19 questions. Between the time you were in Roxane's</p> <p>20 financial department, between 1996 and 2005, did</p> <p>21 you view Roxane as a separate company from BIC and</p> <p>22 BIPI?</p>
<p style="text-align: right;">199</p> <p>1 Roxane made \$175 million from the divestiture of</p> <p>2 the Elan products?</p> <p>3 A. Yes.</p> <p>4 MR. FAUCI: Objection to form.</p> <p>5 BY MS. RIVERA:</p> <p>6 Q. I mean the divestiture of the products to</p> <p>7 -- to Elan.</p> <p>8 A. Yes.</p> <p>9 Q. Okay. And can you tell from your</p> <p>10 knowledge and from your review of the documents</p> <p>11 whether that income was budgeted for in -- for</p> <p>12 Roxane for 2001?</p> <p>13 A. I could -- yes, it was -- it was not</p> <p>14 budgeted for.</p> <p>15 Q. Okay. So is this consistent with your</p> <p>16 testimony that in 2001 Roxane had a unbudgeted</p> <p>17 influx of income in the amount of \$175 million?</p> <p>18 A. Yes.</p> <p>19 Q. Okay. And that contributed in part to</p> <p>20 the reason why the 2002 dividend payment was</p> <p>21 higher?</p> <p>22 A. That would be --</p>	<p style="text-align: right;">201</p> <p>1 MR. FAUCI: Objection --</p> <p>2 BY THE WITNESS:</p> <p>3 A. Yes.</p> <p>4 MS. RIVERA: -- to the form.</p> <p>5 BY THE WITNESS:</p> <p>6 A. Yes.</p> <p>7 MS. RIVERA: What's your objection?</p> <p>8 MR. FAUCI: It calls for a legal</p> <p>9 conclusion.</p> <p>10 BY MS. RIVERA:</p> <p>11 Q. Okay. In your view, was Roxane a</p> <p>12 separate company from BIC and BIPI?</p> <p>13 MR. FAUCI: Same objection.</p> <p>14 BY THE WITNESS:</p> <p>15 A. Yes, they were a separate legal entity.</p> <p>16 BY MS. RIVERA:</p> <p>17 Q. Okay. And following the reorganization</p> <p>18 in 2005, was it your opinion that BIRI was a</p> <p>19 separate -- or did you consider BIRI a separate</p> <p>20 company from BIC, BIPI and RLI at that point?</p> <p>21 A. Yes, it was -- again, it was a separate</p> <p>22 legal entity, separate tax ID.</p>

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com